Real-World Clinical Effectiveness of Loncastuximab Tesirine Monotherapy for the Treatment of Relapsed/ Refractory Diffuse Large B-cell Lymphoma Following Chimeric Antigen T- Cell Therapy in the US

被引：0
|
作者：
Epperla, Narendranath [1 ]
Lucero, Melanie [2 ]
Bailey, Tom [3 ]
Mirams, Laura [3 ]
Cheung, Jolenta [3 ]
Amet, Mona [3 ]
Milligan, Gary [3 ]
Keir, Chris [4 ]
Chen, Lei [5 ]
机构：
[1] Ohio State Univ, Columbus, OH USA
[2] ADC Therapeut Amer Inc, New Providence, NJ USA
[3] Adelphi Real World, Macclesfield, Cheshire, England
[4] ADC Therapeut, Murray Hill, NJ USA
[5] ADC Therapeut, New Providence, NJ USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
loncastuximab tesirine; CD19-targeted chimeric antigen receptor T-cell therapy; real-world evidence; treatment sequencing;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-370
引用
收藏
页码：S476 / S476
页数：1
相关论文
共 50 条
  • [31] REAL-WORLD TREATMENT PATTERNS AND COSTS IN RELAPSED AND REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES
    Mutebi, A.
    Jun, M.
    Flores, C.
    Wang, Z.
    Wang, A.
    Elliot, B.
    Navarro, F. R.
    Kalsekar, A.
    VALUE IN HEALTH, 2022, 25 (07) : S394 - S394
  • [32] Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma
    Seyedin, Roxanna
    Snider, Julia T.
    Rajagopalan, Krithika
    Wade, Sally W.
    Gergis, Usama
    FUTURE ONCOLOGY, 2023, 19 (22) : 1535 - 1547
  • [33] Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma
    Hu, Bei
    Vaidya, Rakhee
    Ahmed, Ferdous
    Ehsan, Hamid
    Moyo, Tamara K.
    Jacobs, Ryan W.
    Pang, Yifan
    Park, Steven
    Wallander, Michelle L.
    Shroff, Vishal
    Boseman, Victoria
    Beam, Travis
    Elder, Jennifer
    Yountz, Melissa
    Jennings, Rebecca
    Howard, Dianna S.
    Avalos, Belinda
    Copelan, Edward A.
    Mesa, Ruben
    Ghosh, Nilanjan
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (11):
  • [34] Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma
    Lin, John K.
    Muffly, Lori S.
    Spinner, Michael A.
    Barnes, James, I
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (24) : 2105 - +
  • [35] Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma
    Ahmed, Nausheen
    Hamadani, Mehdi
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1313 - 1320
  • [36] The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
    Calabretta, Eleonora
    Hamadani, Mehdi
    Zinzani, Pier Luigi
    Caimi, Paolo
    Carlo-Stella, Carmelo
    BLOOD, 2022, 140 (04) : 303 - 308
  • [37] Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Combined with Zanubrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Wang, Langqi
    Yang, Jilong
    Jin, Bo
    Wang, Bo
    Zhou, Lijuan
    Zhuo, Yaqi
    Chen, Huifang
    Chang, Lung-Ji
    Tu, Sanfang
    Li, Yuhua
    BLOOD, 2023, 142
  • [38] Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Lin, Richard J.
    Lobaugh, Stephanie M.
    Pennisi, Martina
    Chan, Jason T.
    Batlevi, Yakup
    Ruiz, Josel D.
    Elko, Theresa A.
    Maloy, Molly A.
    Batlevi, Connie Lee
    Dahi, Parastoo B.
    Giralt, Sergio A.
    Mead, Elena
    Noy, Ariela
    Palomba, Maria Lia
    Santomasso, Bianca
    Sauter, Craig S.
    Scordo, Michael
    Shah, Gunjan L.
    Korc-Grodzicki, Beatriz
    Kim, Soo Jung
    Silverberg, Mari Lynne
    Brooklyn, Chelsea A.
    Devlin, Sean M.
    Perales, Miguel-Angel
    BLOOD, 2019, 134
  • [39] Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma
    Hamadani, Mehdi
    Chen, Lei
    Song, Yan
    Xu, Michael K.
    Liao, Laura
    Caimi, Paolo F.
    Carlo-Stella, Carmelo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (08): : E738 - E744
  • [40] Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era
    Song, Zhiqiang
    Xu, Lili
    Tang, Gusheng
    Gao, Lei
    Wang, Libing
    Ni, Xiong
    Chen, Li
    Chen, Jie
    Wang, Tao
    Feng, Dongge
    Yu, Xuejun
    Yang, Jianmin
    Wang, Yang
    CLINICA CHIMICA ACTA, 2022, 532 : 72 - 78
12345